C.R. Burkholder et al. / Journal of Fluorine Chemistry 109 92001) 39±48
47
Table 4
Although, the results of these studies have demonstrated
that ¯uorine atom substitution can enhance the activity
against HIV substantially, it must be concluded from the
advanced screening that there is no unusual activity against
drug resistant mutant strains of HIV induced by ¯uorine
atom substitution. Consequently, even the most active com-
pound -44) resulting from this work is unlikely to be
clinically useful in the treatment of AIDS.
Effective concentrations -EC50) for 43 and 44 against drug-resistant mutant
strains of HIV
Entry
Strain
EC50 Â 10À6 M
43
44
1
2
3
4
5
6
7
8
9
HIV-1 -III B)
ddI
3.36
0.067
0.159
Inactive
0.373
4.08
4 Â AZT -AZT-R)
OC/100
Inactive
0.38
The gem-di¯uorinated alcohols 17, 18 and 20±24 have
shown no interesting activity.
HEPT/236
Calo
8.64
3.2
0.11
0.43
Diphenyl sulfone
HIV-2 -ROD)
SIV -B670)
Inactive
Inactive
Inactive
Inactive
Inactive
Inactive
References
[1] M.J. Tozer, T. Herpin, Tetrahedron 52 -1996) 8619.
[2] J.T. Welch, S. Eswarakrishnan, Fluorine in Bioorganic Chemistry,
Wiley, New York, USA, 1991.
Secondly, only compounds with six-membered rings such as
benzene, pyridine, or pyrimidine rings attached to the sulfur
were active, while compounds with ®ve-membered rings
such as 41, 42, 46±48 were inactive. Of the compounds with
six-membered rings, it was found that the pyrimidine ring
was most active, followed by the pyridine ring, and then the
benzene ring. This conclusion follows by comparing the
activities of compounds 43 -entry 3), 40 -entry 5), and 39
-entry 7). Furthermore, the activity of the pyrimidine-sub-
stituted compound is greatly enhanced by the addition of a
methyl group in the four-positon of the pyrimidine ring as in
44 -entry 1), which was the most active compound in this
study. The addition of a second methyl produced a decrease
in the activity. Nearly all of the active compounds had a
sulfur atom in the tether connecting the two heterocyclic
rings, while compounds with an oxygen in place of the sulfur
were all inactive except for 52 -entry 4). From comparing the
activity of 39 -entry 7) to 50 which was inactive, it can be
concluded that having a sulfur in the tether rather than an
oxygen, enhances the activity. Lastly, but most importantly,
a comparison of the activity of the ¯uorine-containing
compound 43 -entry 3), to the hydrogen-substituted analog
57 -entry 6), leads to the conclusion that ¯uorine substitution
is responsible for a 10-fold increase in activity. It is inter-
esting to speculate why this may be so. The ¯uorine atoms
may enhance the lipophilicity of the adjacent benzoxazole
ring, thus, increasing its binding to the lipophilic pocket of
the binding site of the reverse transcriptase enzyme. If this is
the case, then it may well be that this enhancement of
activity by ¯uorine substitution, could be applicable to many
other biologically active compounds where it is possible to
replace a CH2 group which is adjacent to an aromatic ring
with a CF2 group.
Â
[3] M. Medebielle, Tetrahedron Lett. 37 -1996) 5119.
Â
[4] M. Medebielle, Tetrahedron Lett. 36 -1995) 2071.
[5] Z.-M. Qiu, D.J.J. Burton, J. Org. Chem. 60 -1995) 5570.
[6] T. Itoh, H. Ohara, S. Emoto, Tetrahedron Lett. 36 -1995) 3531.
[7] L.A. Buttle, W.B. Motherwell, Tetrahedron Lett. 35 -1994)
3995.
[8] S.T. Patel, J.M. Percy, R.D.J. Wilkes, J. Org. Chem. 61 -1996) 166
and references therein.
[9] K. Burger, U. Wucherpfennig, E. Brunner, Adv. Heterocyclic Chem.
60 -1994) 1.
[10] B.-H. Luo, H.-P. Guan, C.-M. Hu, Synlett. -1997) 1261.
[11] W.F.J. Goure, J. Heterocyclic Chem. 30 -1993) 71.
[12] M.S. South, K.A.J. Van Sant, J. Heterocyclic Chem. 28 -1991) 1017.
[13] B.C.J. Hamper, Fluorine Chem. 48 -1990) 123.
[14] K. Morimoto, K. Makino, S. Yamamoto, G.J. Sakata, J. Heterocyclic
Chem. 27 -1990) 807.
[15] S. Fujii, K. Kimoto, Y. Maki, Rep. Gov. Ind. Res. Inst. Nagoya 35 -3)
-1986) 117; Chem. Abstr. 106 -1987) 156352j.
Â
[16] S. Fujii, K. Kato, M. Medebielle, Tetrahedron 56 -2000) 2655.
[17] Y. Xu, W.R. Dolbier Jr., J. Org. Chem. 65 -2000) 2134.
[18] Y. Xu, W.R. Dolbier Jr., Tetrahedron Lett. 39 -1998) 9151.
[19] Y. Xu, W.R. Dolbier Jr., Tetrahedron 54 -1998) 6319.
[20] Y. Xu, W.R. Dolbier Jr., J. Org. Chem. 62 -1997) 1576.
 Â
[21] M. Medebielle, J. Pinson, J.-M. Saveant, Electrochim. Acta 42 -1997)
2049.
[22] Y. Xu, W.R. Dolbier Jr., J. Org. Chem. 62 -1997) 6503.
 Â
[23] M. Medebielle, M.A. Oturan, J. Pinson, J.-M. Saveant, J. Org. Chem.
61 -1996) 1131.
Â
[24] M. Medebielle, Tetrahedron Lett. 37 -1996) 5119.
[25] W.R. Dolbier Jr., C.R. Burkholder, K.A. Abboud, D.J. Loehle, J. Org.
Chem. 59 -1994) 7688.
Â
[26] C.R. Burkholder, W.R. Dolbier Jr., M. Medebielle, A. Ndedi,
Tetrahedron Lett. 39 -1998) 8853.
[27] C.R. Burkholder, W.R. Dolbier Jr., M.J. Medebielle, J. Org. Chem. 63
Â
-1998) 5385.
Â
[28] C.R. Burkholder, W.R. Dolbier Jr., M. Medebielle, Tetrahedron Lett.
38 -1997) 821.
[29] C.R. Burkholder, W.R. Dolbier Jr., M.J. Medebielle, J. Fluorine
Â
Chem. 102 -2000) 369.
Compounds 43 and 44 were referred for testing in the
advanced screens, and the results can be seen by looking at
Table 4. Although, the activity of 44 against the wild type
HIV-1 -III B) was very good -entry 1), it was inactive against
a number of mutant strains of HIV -entries 3, 7, 8, and 9).
Compound 43 was similarly inactive in a number of cases
-entries 2, 7, 8, and 9).
[30] J.M. Hoffman, A.M. Smith, C.S. Rooney, T.E. Fisher, J.S. Wai, C.M.
Thomas, D.L. Bamberger, J.L. Barnes, T.M. Williams, J.H. Jones,
B.D. Olson, J.A. O'Brien, M.E. Goldman, J.H. Nunberg, J.C.
Quintero, W.A. Schleif, E.A. Emini, P.S,J. Andersen, J. Med. Chem.
36 -1993) 953 and references therein.
Â
[31] C.R. Burkholder, W.R. Dolbier Jr., M.J. Medebielle, J. Fluorine
Chem. 95 -1999) 127.
[32] G.J. Pawelke, J. Fluorine Chem. 52 -1991) 229.